ENTITY
WP107
WP107
PulseAugur coverage of WP107 — every cluster mentioning WP107 across labs, papers, and developer communities, ranked by signal.
Total · 30d
2
2 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
TOPICS
TIMELINE
- 2026-07-16 regulatory WP107, a new drug for generalized myasthenia gravis, received FDA approval for multi-dose dose-climbing clinical trials in healthy participants. source
SENTIMENT · 30D
1 day(s) with sentiment data
RECENT · PAGE 1/1 · 2 TOTAL
-
UnitedHealth Group raises EPS forecast; new drug approved for trials
UnitedHealth Group reported second-quarter revenue of $112.03 billion, exceeding expectations. The company also raised its full-year adjusted earnings per share forecast to $19.50-$20.00, up from over $18.25. In other n…
-
ST Wanbang's Myasthenia Gravis Drug WP107 Gains FDA Approval for Clinical Trials
ST Wanbang's subsidiary, Wanbangde Pharmaceutical Group, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a multi-dose dose-climbing clinical trial for its new drug, WP107. This drug is …